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Background
NO-sensitive guanylyl cyclases (NO-GC’s) that catalyze
the reaction of GTP to the second messenger molecule
cGMP are heterodimeric enzymes consisting of an a
and a b1 subunit. The two prevalent isoforms in humans
(a1/b1, a2/b1) are time-tested targets for drugs that
release nitric oxide (NO) and new compounds that
either sensitize the enzyme for activation by NO or acti-
vate the enzyme independently of NO. Homologous
NO-GC subunits consist of an amino-terminal HNOX
domain followed by a PAS- and a coiled coil domain
and the carboxy-terminal catalytic domain.
Results
Measurement of FRET between fluorescent proteins
tagged to the amino- and carboxy-terminus of the subu-
nits indicated close proximity between the amino-terminal
HNOX domains and the carboxy-terminal catalytic
d o m a i n so ft h ee n z y m e .O nt h eb a s i so ft h e s er e s u l t sw e
constructed conjoined NO-GC’sb yf u s i o no ft h ea amino-
terminus to the b1 carboxy-terminus leading to a mono-
meric enzyme complex. Surprisingly but in accordance
with the FRET results these conjoined NO-GC’s( b1a1,
b1a2) showed specific enzyme activity and stimulation by
NO and various modulators of GC activity.
Conclusion
These obligate enzyme variants faithfully reproduced the
pharmacological properties of the heterodimeric enzymes
including an isoform specific differential activation of the
NO-independent drug cinaciguat. Novel applications of
conjoined NO-GC’s including adenoviral gene transfer
will be discussed.
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